European Union medical cannabis trade: Germany imported more than 50 tonnes in Q1 2026

The number that resets the European benchmark

The core figure comes from newly published BfArM figures highlighted by Newsweed. In the first quarter of 2026, Germany imported at least 50.539 tonnes of medical cannabis products. For an international reader, that is the key measure of scale: one European Union member state brought in more than 50 tonnes of regulated medical supply in three months through a pharmacy channel that has existed since 2017.

The latest benchmarks are stark:

At the logistics level, that dominance looks like this:

Those numbers matter beyond Germany’s borders. The same primary report says the country imported more than 218 tonnes over the latest 12 months, confirming its position as Europe’s largest legal medical cannabis market and the world’s leading destination for imported medical cannabis products. For exporters, compliance advisers and EU distributors, Germany is the market that turns regulatory approval into real volume.

A quarterly dip inside a much bigger annual surge

The market is still enormous, but the newest quarter was not a fresh high. According to trade reporting on the BfArM release, the Q1 total was down from a revised 60.8 tonnes in Q4 2025, marking the first quarter-on-quarter decline since early 2024. That is a notable break in momentum, but it is not the same thing as a reversal of the longer trend.

The latest two reported quarters look like this:

Even with that pullback, the first quarter of 2026 remains exceptionally high by European standards. A market can cool from one record-like reading to another without losing its regional dominance.

Set against the main reference points mentioned in the reporting, the scale is clearer:

The United Kingdom comparison is brief but useful precisely because it sits outside the European Union. The primary source says the UK, often treated as Europe’s second-largest medical cannabis market, imported about 30 tonnes in 2025. That leaves Germany’s lower Q1 2026 result looking less like weakness and more like consolidation at a far larger scale.

Domestic supply and new legal routes are changing the mix

The most plausible explanation offered in the primary reporting is not a collapse in demand but a shift in how demand is being met. Imports remain the cornerstone of Germany’s medical system, yet domestic cultivation has been expanding since the 2024 CanG removed production quotas that had previously limited commercial growing. As local output rises, part of the demand once met entirely by foreign suppliers can be absorbed inside the country.

The policy sequence behind that change is straightforward:

The main channels now sitting alongside imported pharmacy supply are these:

• Pharmacy dispensing has been available since 2017, turning what began as a limited patient-access programme into a mature market.
• After CanG was adopted in 2024, Germany removed earlier production quotas for commercial cultivation, allowing domestic capacity to grow.
• Since April 2024, adults in Germany may grow up to three plants at home.
• Since July 2024, non-profit cultivation associations may grow and distribute cannabis to registered members under strict rules.
• The primary source says Germany has already licensed more than 430 cultivation associations.

The club layer is also becoming easier to track in practice, as shown when four German states published cannabis social club lists. What the supplied facts do not show is how much medical demand, if any, has already migrated from pharmacies to home growing or club access.

That leaves Europe with a more layered supply picture than a single import number suggests:

That ambiguity is important for European Union observers. A market can diversify internally while remaining the bloc’s main import hub externally. On the facts available here, Germany may be doing both at once.

Why Germany matters to the European Union far beyond its own patients

The EU angle is what makes the German import total more than a national statistic. According to the primary reporting, Canada remains the leading supplier into Germany because Canadian producers spent years building export capacity and securing the certifications required for European pharmaceutical markets. In practice, that makes Germany the bloc’s main proving ground for companies seeking scale in legal medical cannabis.

Germany remains Europe’s leading legal medical cannabis market and the world’s top destination for imported medical cannabis products.

Newsweed, citing BfArM data

This sits inside a wider European environment in which cannabis policy is still moving in several directions at once. As we reported in Cannabis – the current situation in Europe (European Drug Report 2026), the European Union Drugs Agency says cannabis remains the region’s most used illicit substance and that products, markets and enforcement challenges are becoming more complex. Germany’s legal medical import machine is therefore developing alongside a much broader and uneven continental debate.

At ground level, that trade looks less like ideology and more like regulated pharmaceutical distribution:

That is why Germany’s import figures are watched well beyond Berlin. When one EU member state can import more than 50 tonnes in a quarter, supplier planning, certification investment and market strategy across Europe tend to follow its lead.

The next question is not whether the market is big, but how stable access will be

Import data alone cannot answer whether patient access is getting easier, harder or simply more diversified. They show scale. They do not show how many people are using medical cannabis, how many are shifting to domestic routes, or how future reimbursement rules might reshape demand.

That last point deserves attention. Germany is simultaneously debating future reimbursement rules for some medical cannabis prescriptions, a separate policy fight we covered in the Bundestag debate over a possible reimbursement cutoff for cannabis flowers. If insurance coverage narrows while domestic production and club access expand, headline import volumes may become a less complete guide to how the market is functioning.

For readers tracking the European Union market, the practical questions are these:

What remains unmistakable is that Germany is still the European Union’s reference point. A quarter that counts as a slowdown there would still amount to a defining benchmark almost anywhere else in Europe.